Medical Device Hazard Analysis Services

Medical device hazard analysis services help manufacturers identify foreseeable hazards, estimate and evaluate associated risks, define risk controls, and document residual risk in a structured, traceable way. These services typically support ISO 14971-compliant risk management, technical documentation, design controls, labeling decisions, and regulatory submissions for FDA, EU MDR, TGA, and other markets.

Hazard analysis is critical because it demonstrates that device risks have been systematically identified and reduced as far as appropriate. Regulators and auditors expect risk decisions to be supported by evidence, linked to design inputs, verification, validation, labeling, and post-market data. Weak hazard analysis can delay submissions, trigger audit findings, and undermine the credibility of your overall technical documentation.

ISO 14971 is the core standard for medical device risk management, and hazard analysis is one of its central activities. It supports hazard identification, hazardous situation analysis, risk estimation, risk evaluation, risk control implementation, and residual risk review. A strong hazard analysis should also connect to your risk management plan, risk management report, and ongoing post-market risk monitoring.

Yes. Elexes supports remediation of incomplete or inconsistent risk management files by reviewing existing documentation, identifying structural and traceability gaps, and rebuilding the file to align with applicable standards and regulatory expectations. This can include updating hazard tables, risk acceptability logic, control verification links, benefit-risk rationale, and integration with DHF, clinical, and post-market records.

Yes. Hazard analysis is often reviewed closely in both FDA and EU MDR pathways because it affects safety claims, testing rationale, labeling, and overall submission credibility. Elexes helps align risk documentation with FDA expectations, ISO 14971 principles, EU MDR Annex I requirements, GSPR evidence, and the broader technical file so reviewers can follow the safety logic clearly.

Hazard analysis should be updated whenever there are meaningful changes to design, software, materials, manufacturing processes, intended use, labeling, or post-market safety information. It should also be reviewed before major submissions, during remediation work, after complaint trends emerge, and when verification, validation, or clinical evidence changes the understanding of device risk.

Yes. SaMD products often require focused hazard analysis tied to software functionality, failure modes, user interaction, cybersecurity considerations, and software lifecycle controls. Elexes supports SaMD manufacturers by aligning risk documentation with intended use, software architecture, IEC 62304 expectations, and the evidence needed for regulatory submissions and ongoing quality system governance.

Typical deliverables may include a gap assessment of current risk documentation, updated hazard analyses, revised risk management file sections, traceability improvements, remediation plans, and submission-supporting documentation. Depending on scope, the engagement can also include DHF alignment, change impact assessments, labeling risk review, and integration of hazard analysis outputs with clinical, PMS, and quality system records.